http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김두화,박정환,한도수,허선아,김성현,조성동 조선대학교 기초과학연구소 1992 自然科學硏究 Vol.15 No.1
The reaction of Asymmetrical organotins with acid chlorides in the presence of Benzylbis (triphenylphosphine) palladium(Ⅱ) chloride gave good yields of ketones in chloroform.
임신 중 환경오염물질 2-Bromopropane에 노출된 마우스의 모독성 평가
허정두(Jeong-Doo Heo),김충용(Chung-Yong Kim),강성철(Chen-Zhe Ziang),서정은(Jeong-Eun Suh),정문구(Moon-Koo Chung),김무강(Moo-Kang Kim),신동호(Dong-Ho Shin),김종춘(Jong-Choon Kim) 한국실험동물학회 2004 Laboratory Animal Research Vol.20 No.1
2-Bromopropane (2-BP), a halogenated propane analogue, is a substitute for chlorofluorocarbones (CFCs). The present study was carried out to investigate the potential adverse effects of 2-BP on pregnant dams after maternal exposure during the gestational days (GD) 6 through 17 in ICR mice. The test chemical was administered subcutaneously to pregnant mice at dose levels of 0, 500, 1000, and 1500 ㎎/㎏/day. All pregnant females were subjected to autopsy on GD 18. Treatment-related clinical signs, as evidenced by dose-dependent increases in the incidence and severity of rough fur, swelling, induration, crust formation, and ulceration at the injection sites, were observed at dose levels of above 1000 ㎎/㎏/day. Maternal body weight on GD 18 and maternal body weight gain for the intervals GD 6-17 (treatment period) were suppressed at a dose level of 1500 ㎎/㎏ in a dose-dependent manner, but not statistically significant. Hematological investigations revealed a dose-dependent decrease in the number of platelet at a dose level of 1500 ㎎/㎏. Fetal body weights of both sexes in the 1500 ㎎/㎏ group were also decreased in a dose-dependent manner. There were no adverse effects on mortality, food consumption, organ weights, and reproductive findings except for decreased fetal body weight in any treatment group. Based on these results, it was concluded that the 12-day repeated subcutaneous dose of 2-BP resulted in an increased incidence of clinical signs, suppressed maternal body weight, reduced platelet count and decreased fetal body weight at a dose level of 1500 ㎎/㎏/day in pregnant mice. In the present experimental conditions, the no-observed-adverse-effect level of 2-BP was considered to be 500 ㎎/㎏ for dams.
Jeong-Ah Song,Hyo-Seon Yang,Jinsoo Lee,Soonjin Kwon,Kyung Jin Jung,Jeong-Doo Heo,Kyu-Hyuk Cho,Chang Woo Song,Kyuhong Lee 한국독성학회 2010 Toxicological Research Vol.26 No.3
Bronchoalveolar lavage (BAL) is a useful tool in researches and in clinical medicine of lung diseases because the BAL fluid contains biochemical and cytological indicators of the cellular response to infection, drugs, or toxicants. However, the variability among laboratories regarding the technique and the processing of the BAL material limits clinical research. The aim of this study was to determine the suction frequency and lavage fraction number necessary to reduce the variability in lavage using male Sprague-Dawley rats. We compared the total cell number and protein level of each lavage fraction and concluded that more cells and protein can be obtained by repetitive lavage with a suction frequency of 2 or 3 than by lavage with a single suction. On the basis of total cell recovery, approximately 70% of cells were obtained from fractions 1~3. The first lavage fraction should be used for evaluation of protein concentration because fractions 2~5 of lavage fluid were diluted in manifolds. These observations were confirmed in bleomycin-induced inflamed lungs of rats. We further compared the BAL data from the whole lobes with data from the right lobes and concluded that BAL data of the right lobes represented data of the whole lobes. However, this conclusion can only be applied to general lung diseases. At the end, this study provides an insight into the technical or analytical problems of lavage study in vivo.
허천(Heo Cheon),정우진(Jeong Woo-Jin),염두승(Yeom Doo-Seoung) 한국체육과학회 2001 한국체육과학회지 Vol.10 No.2
Based on the above research, the conclusion is as follows regarding the improvements of the park athletic facilities. 1. The public athletic facilities should always be open to the local self-governing bodies. They should expand the insufficient facilities considering regional circumstances for the public to utilize them efficiently. 2. Each region should make financial contributions to enlarge the athletic facilities through a fixed budget The main source of income will be provided through the leasing of the athletic facilities. 3. Every region should meet the necessities of the local citizens. Each facility should take into account the organization, program, and use for the public. Most importantly, each facility should educate the general public on exercise and the benefits of good health. 4. Most of the people have a lot of spare time and are apt to take part in social athletics. So each region should plan and develop a variety of programs democratically according to the properties of the participants.
Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects
( Hyo Jeong Lee ),( Yeongyu Moon ),( Jungil Choi ),( Jeong Doo Heo ),( Sekwang Kim ),( Hari Krishna Nallapaneni ),( Young-won Chin ),( Jongkook Lee ),( Sun-young Han ) 한국응용약물학회 2022 Biomolecules & Therapeutics(구 응용약물학회지) Vol.30 No.4
Tropomyosin receptor kinase A (TrkA) protein is a receptor tyrosine kinase encoded by the NTRK1 gene. TrkA signaling mediates the proliferation, differentiation, and survival of neurons and other cells following stimulation by its ligand, the nerve growth factor. Chromosomal rearrangements of the NTRK1 gene result in the generation of TrkA fusion protein, which is known to cause deregulation of TrkA signaling. Targeting TrkA activity represents a promising strategy for the treatment of cancers that harbor the TrkA fusion protein. In this study, we evaluated the TrkA-inhibitory activity of the benzoxazole compound KRC-108. KRC-108 inhibited TrkA activity in an in vitro kinase assay, and suppressed the growth of KM12C colon cancer cells harboring an NTRK1 gene fusion. KRC-108 treatment induced cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 suppressed the phosphorylation of downstream signaling molecules of TrkA, including Akt, phospholipase Cγ, and ERK1/2. Furthermore, KRC-108 exhibited antitumor activity in vivo in a KM12C cell xenograft model. These results indicate that KRC-108 may be a promising therapeutic agent for Trk fusion-positive cancers.
Pectolinarigenin suppresses the tumor growth in gastric cancer
Ho Jeong Lee,Ju Hong Lee,Je-Hein Kim,Jeong Doo Heo 한국실험동물학회 2021 한국실험동물학회 학술발표대회 논문집 Vol.2021 No.7
Gastric cancer (GC) is identified as the second leading cause of death as one of the common recorded cancer cases in the world. Even though the mortality rate of gastric cancer remains the second leading cause of death worldwide and it is still the most prevalent cancer in Eastern Asis. It is known the natural flavonoid, pectolinarigenin (PEC) contains in Cirsium chanroenicum and citrus fruits. In a previous study, we investigated the mechanism of PEC-induced cellular response such as apoptosis and autophagy in gastric cancer cells. In the present study, we conducted the anti-cancer effect of PEC by xenograft mouse model. AGS human gastric cancer cells were cultured and subcutaneous to Balb/c nude mice to make a xenograft mouse model was established to evaluate the anti-tumor effect of PEC in vivo. After finished in vivo experiment, mice were sacrificed and tear off the tumor for comparative proteomic analysis was performed to identify proteins associated with PEC-suppressed tumor. We observed their tumor volume and tumor weight reduced in the PEC treatment group than the control group, that treatment of PEC suppressed tumor in the xenograft mice model dose-dependent manner. In addition, body weight and hematological analysis showed that PEC was not toxic in the xenograft mice model. We identified 616 proteins related to cellular response such as tumorigenesis and cell death signal in the tumor of xenograft mice model by LC-MS analysis. Thus, PEC treatment might suppress the tumor growth of GC and the proteomic analysis provides basic information about target proteins that are important for novel GC therapeutic agent. In a further study, we will find out which proteins play a role in GC suppression.
능동식 대중교통 우선신호에서 신호시간 낭비를 방지하기 위한 신호연동모형
정영제 ( Jeong Young-je ),정준하 ( Jeong Hun-ha ),주두환 ( Joo Doo-hwan ),이호원 ( Lee Ho-won ),허낙원 ( Heo Nak-won ) 한국도로교통공단 2014 교통안전연구 Vol.33 No.-
본 연구에서는 능동식 우선신호의 현시낭비를 정의하고, 간선도로 신호교차로 연동모형인 MAXBAND를 이용해 현시낭비 방지모형을 제시하였다. 우선신호를 제공받아 교차로를 통과한 대중교통이 인접한 하류부 교차로에서 다시 적색시간에 도착하게 됨으로써 우선신호의 효율성을 떨어뜨리게 되는 상황을 능동식 우선신호의 현시낭비로 정의하였으며, MAXBAND-MILP2 모형을 이용하여 현시낭비를 방지하기 위한 추가 제약조건을 제시하였다. 우선신호가 제공되는 조건에서의 시공도 상에서의 대중교통 주행궤적을 이용하여 제약조건을 작성하였으며, Early Green과 Green Extension에서 발생하는 현시낭비를 방지할 수 있도록 하였다. 사례분석 결과 현시낭비 방지를 위한 추가제약조건으로 인해 연동폭의 감소가 발생하나, 대중교통이 교차로에서 불필요한 추가지체를 발생시키지 않는 연동폭 산정이 가능함을 확인하였다. 본 연구는 전통적인 간선도로 신호최적화 모형을 수정하여 우선신호에 적합한 신호시간 산정방법을 제시하였다는데 의의가 있으며, 광역 BRT, 트램 등 우선신호가 요구되는 대중교통 운영환경이 확산되고 있는 상황에서 우선신호 운영효율성을 제고하는데 기여할 수 있을 것으로 판단된다. In this research, phase waste of active signal priority is defined and new phase waste prevention model is proposed. This model was formulated based on the MAXBAND MILP-2 model, which is a traditional arterial signal optimization model to maximize green bandwidth. The phase waste is defined as a poor efficiency condition of signal progression which a transit that is provided with an active signal priority stops again at the downstream intersection. This research suggested additional constraints of MAXBAND MILP-2 model to prevent the phase waste condition. The transit progression constraints are suggested using transit trajectories and time-space diagram for Early Green and Green Extension techniques. In case study, additional constraints to prevent phase waste reduce general green bandwidth to guarantee the transit progression. However, this progression condition could reduce unnecessary transit delay at the signal intersection. There is signification in regard to suggest signal timing optimization method for active transit signal priority using traditional arterial progression model.